pHOXBIO’s nasal spray prevents SARS-CoV-2 infection in Phase II/III trial
Nearly 13.1% of subjects in the pHOXWELL arm were tested positive for Covid-19 versus 34.5% in the placebo arm.
Infectious Diseases
Gilead’s Veklury reduces hospitalisation risk in Phase III Covid-19 trial
By day 28, subjects receiving Velkury had an 81% reduction in risk of medical visits...
Feinstein starts third Moderna Covid vaccine trial for transplant patients
The trial plans to enrol 240 subjects to evaluate immune antibody response 28 days following...
Ampio obtains DCGI approval for Phase II Covid-19 trial of inhaled drug
In the trial, inhaled Ampion will be used to treat patients with respiratory distress associated...
Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape
Questions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
Rhizen doses first subject in Phase II Covid-19 oral drug trial in India
The Phase II trial will enrol up to 204 Covid-19 patients at across 12 study centres in India.
Waning Covid-19 vaccine efficacy: what does the data show?
While Covid-19 vaccines’ protection does appear to wane, most experts agree that universal booster rollouts aren’t needed yet.
Gritstone starts Phase I dosing of second-gen mRNA Covid-19 vaccine
The trial will test the safety, tolerability and immunogenicity of two dose levels of the vaccine given as a booster to Vaxzevria.
Eiger obtains DSMB approval to progress Phase III Covid-19 therapy trial
The recommendation follows an interim futility analysis conducted by the panel on a sample size of 453 subjects.
Appili concludes enrolment in sub-study of Covid-19 antiviral treatment
The sub-study enrolled more than 550 subjects to analyse Avigan/Reeqonus’ efficacy against Covid-19 variants.
UK trial to assess mixed Covid-19 vaccine regimens in adolescents
Subjects will receive a first dose of the Pfizer-BioNTech vaccine and a second dose of either Pfizer, Novavax or Moderna.
